Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: Ertapenem sterilizing effect versus Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3193-3195

  Srivastava, Shashikant ^a   Van Rijn, Sander P ^b   Wessels, A Mireille A ^b   Alffenaar, Jan Willem C ^b   Gumbo, Tawanda ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; FROPENEM; MEROPENEM; RESAZURIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; CORRELATION COEFFICIENT; EC50; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RESAZURIN ASSAY; TUBERCULOSIS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 84964989357     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02924-15     Document Type: Article

References (14)

1. Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, Alffenaar JW, Migliori GB. 2016. Ertapenem in the treatment of multidrug- resistant tuberculosis: first clinical experience. Eur Respir J 47:333-336. http://dx.doi.org/10.1183/13993003.01278-2015.
2. Van Rijn SP, Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC. 7 January 2016. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur Respir J. http://dx.doi.org/10 .1183/13993003.01654-2015.
3. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. 2013. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 41:1386-1392. http://dx.doi.org/10.1183/09031936.00124312.
4. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321-338. http://dx.doi.org/10.1016/S2213-2600(14)70031-1.
5. Cordillot M, Dubee V, Triboulet S, Dubost L, Marie A, Hugonnet JE, Arthur M, Mainardi JL. 2013. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob Agents Chemother 57:5940-5945. http://dx.doi.org/10.1128/AAC.01663-13.
6. European Medicines Agency. 2004. Scientific discussion for the approval of Invanz. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library /EPAR-Scientific-Discussion/human/000389/WC500033918.pdf.
7. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197-3204. http://dx .doi.org/10.1128/AAC.01681-08.
8. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, Meek C, Leff R, Pasipanodya J, Gumbo T. 2013. Thioridazine pharmacokineticpharmacodynamic parameters "wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother 57:5870-5877. http://dx.doi .org/10.1128/AAC.00829-13.
9. Hett EC, Rubin EJ. 2008. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 72:126-156, table of contents. http://dx.doi.org/10.1128/MMBR.00028-07.
10. Mitchison DA. 1979. Basic mechanisms of chemotherapy. Chest 76: 771-781.
11. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. CLSI M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Van Rijn SP, Wessels AM, Greijdanus B, Touw DJ, Alffenaar JW. 2014. Quantification and validation of ertapenem using a liquid chromatography- tandem mass spectrometry method. Antimicrob Agents Chemother 58:3481-3484. http://dx.doi.org/10.1128/AAC.00025-14.
13. Srivastava S, Pasipanodya J, Sherman CM, Meek C, Leff R, Gumbo T. 2015. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Antimicrob Agents Chemother 59:2273-2279. http: //dx.doi.org/10.1128/AAC.04441-14.
14. Veziris N, Truffot C, Mainardi JL, Jarlier V. 2011. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 55:2597-2600. http://dx.doi.org/10.1128/AAC .01824-10.